Concise Prescribing Info
Dosage/Direction for Use
Adult: PO 25 mg 3 times/day. Max: 150 mg daily.
Recent MI, arrhythmias, severe liver disease, manic phase. Lactation.
Special Precautions
CV disease, history of epilepsy, hepatic impairment, hyperthyroidism, pheochromocytoma, history of mania, psychoses, close-angle glaucoma, history of urinary retention, concurrent electroconvulsive therapy, diabetes. Pregnancy. Elderly and child. Porphyria. Avoid abrupt withdrawal. May cause drowsiness; do not drive or operate machinery.
Adverse Reactions
Marked antimuscarinic effects, CV effects. Nausea, sweating, tremor, hypersensitivity reactions, behavioral disturbances, sexual dysfunction, blood sugar changes, increased appetite or wt gain. Testicular enlargement, gynecomastia, galactorrhea. Convulsion, movement disorders, dyskinesias. Fever and blood disorders.
Drug Interactions
Plasma conc and effects may be enhanced by concomitant use of cimetidine, diltiazem, disulfiram, methylphenidate, ritonavir and verapamil. Side-effects may be increased by adrenaline, amiodarone, general anesthetics, SSRIs, antihistamines, antimuscarinics, antipsychotics, anxiolytics and hypnotics, clozapine, disopyramide, diuretics, flecainide, MAOIs, moclobemide, moxifloxacin, nefopam, nicorandil, noradrenaline,phenothiazine, pimozide, procainamide, propafenone, quinidine, selegiline, sibutramine, sotalol, terfenadine, thioridazine and tramadol. Clonidine, barbiturates, nitrates and primidone are reduced while effects of baclofen, opioid analgesics and thyroid hormones are enhanced with concomitant use. Carbamazepine and rifampicin may increase metabolism while its effects may be antagonized by estrogens. Alcohol.
CIMS Class
ATC Classification
N06AA15 - butriptyline ; Belongs to the class of non-selective monoamine reuptake inhibitors. Used in the management of depression.
Disclaimer: This information is independently developed by CIMS based on butriptyline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in